The quest for effective treatments for Pelvic Venous Disorder (PeVD) has led to explorations of various techniques, including the use of N-butyl-2 cyanoacrylate (NBCA) glue for ovarian vein embolization (OVE). Recent research sought to illuminate the safety and efficacy of this approach, yet critical concerns arise as we delve into the findings.
A study conducted between January 2013 and January 2020 examined 21 women grappling with PeVD who underwent OVE using NBCA. The initial assessment, encompassing symptoms like chronic pelvic pain (CPP), dyspareunia, dysmenorrhea, and vulvar varices, showed promising results. The technical success of NBCA embolization was unequivocal, with no reported complications related to the adhesive material.
However, it’s crucial to recognize that while NBCA-based OVE exhibits potential, this approach is far from being considered a definitive solution for PeVD. The study’s limited sample size and retrospective nature warrant cautious interpretation. Additionally, the absence of persistent or recurrent CPP during the relatively short follow-up period of 62 ± 38 months raises concerns about the durability of treatment effects over a more extended period.
Furthermore, we must emphasize the need for more comprehensive investigations into the safety profile of this technique. While the 28.6% birth rate post-embolization is intriguing, it is insufficient to establish NBCA-based OVE as the primary choice for women seeking symptom relief while also considering family planning.
In conclusion, the findings suggest that NBCA-based ovarian vein embolization may offer a glimmer of hope for PeVD patients. Nevertheless, we must exercise caution and await larger, more comprehensive studies to genuinely comprehend the efficacy, safety, and long-term implications of using NBCA for PeVD treatment. Until then, a prudent approach is warranted, acknowledging the unresolved complexities and potential complications that persist.